Search results
PROMOTED
Stay up to date with the latest clinical evidence in transthyretin amyloid cardiomyopathy (ATTR-CM) with this video series spotlighting key cardiomyopathy updates presented at ESC Heart Failure Congress (HFA) 2026.In the first session, Dr Mathew Maurer (Columbia University, New York, US) takes a deep dive into the CARDIO-TTRansform data, exploring the current treatment landscape and ongoing unmet…
View more
Spotlight on HFA 2026: Updates on Cardiomyopathies
Added:
1 month ago
Video Series
Added:
2 years ago
HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure…
View more
Added:
2 years ago
HFA 24 - Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE) joins us in this succinct interview to outline the findings of the RELIEVE-HF trial (NCT03499236).RELIEVE-HF was designed to evaluate the safety and effectiveness of the V-Wave inter-atrial shunt system to reduce lung congestion in patients with advanced heart failure. 605 participants with New York Heart Association (NYHA)…
View more
Vericiguat in Real-life Patients with Heart Failure: The VERITA Study
Added:
1 month ago
Original Research
Added:
9 months ago
Source:
Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously…
View more
Obesity Definitions and LOS in Heart Failure
Added:
3 weeks ago
Original Research
Added:
2 years ago
HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had…
View more
Background of Heart Failure
Added:
1 year ago
Review Article
Added:
10 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
Acute Heart Failure Classification
Added:
1 month ago
Review Article